Omniscope

At Omniscope, we read your immune system in high definition: one cell at a time. We are building the world’s largest immune databank. Our vision? Healthcare for everyone, everywhere. 🚀 Thanks for the feature, Google Cloud! 🔗 Learn more about Omniscope technology: https://www.omniscope.ai/ #GoogleCloudSummit #ScienceIsWeAll Google, Vijay Vaswani

Omniscope longitudinal analysis was applied in a multi-dose ovarian cancer vaccine trial. Using advanced statistical and machine learning approaches, and proprietory sequencing, Omniscope technology enabled comprehensive characterization and tracking of immune dynamics. Here, we demonstrate how deep TCR sequencing and analysis can evaluate efficacy of a personalized cancer vaccine. Learn how our team successfully identified vaccine-related T cells and tracked them over multiple time points, assessing the vaccine’s ability to promote immunity against cancer peptides and evaluate duration of immune response: https://lnkd.in/dVMvj5EG #ScienceIsWeAll

Cancer-specific T cells are required for effective anti-cancer immunity, but what are the implications of bystander T cells in tumors? This study discusses recent experimental and computational studies on bystander T cells to develop therapeutic approaches. 🗞️ https://lnkd.in/dyaDV2cB #ScienceIsWeAll #NoTCellLeftBehind

Monitoring patient response to immunotherapy is crucial. Not only for patient's well-being but also for their quality of life. But why subject a patient to potent therapies if there's an 80% chance* of ineffectiveness? Omniscope believes our immune system holds the key to predicting treatment response. By analyzing clonotype diversities and tracking specific clones, we can identify patterns indicative of positive response. Furthermore, comparing immune profiles of known responders allows us to explore varying degrees of response, providing clinical oncologists with valuable insights into what distinguishes a good responder from a poor one. Read more about how Omniscope technology can catalyze identification of positive responders to enable treatment selection and timely intervention in latest poster presentation at ESMO IO: https://lnkd.in/dp4tRRhc #ScienceIsWeAll #NoTCellLeftBehind

We're #hiring a new Laboratory Technician in Barcelona, Catalonia. Apply today or share this post with your network.

Out now! 🚨 Ever wondered how AI can help drive your drug development life cycle forward?↩️ Dive into the inspiring journey of Vijay Vaswani, Co-Founder and CEO of Omniscope as he shares how his passion for tech led to creating a platform revolutionizing drug development that accelerates the path to better patient outcomes. Find out more about Vijay and his episode ⤵️ https://lnkd.in/ewcPy_Vn Don’t forget to subscribe and leave a rating wherever you get your podcast fix! 🎧Apple: https://lnkd.in/eStx36pw 🎧Amazon: https://lnkd.in/e6hTnUcU 🎧Spotify: https://lnkd.in/e_XZZmyq See you at BPI! M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://lnkd.in/eAM55NeD Don't miss out and we'll see you in September! #AI #DrugDevelopment #AutoImmune #PatientOutcomes

CEO Vijay Vaswani delves into AI in Healthcare on Molecule to Market newest episode. Tune in to learn how AI is revolutionizing drug discovery and immune profiling! 🎧 Spotify: https://lnkd.in/dYyvPCEa 🎧 Apple: https://lnkd.in/dnAygS7w 🎧 Amazon: https://lnkd.in/dYYWSqFu #ScienceIsWeAll

This Friday, we have a new episode with Vijay Vaswani, Co-Founder and CEO of Omniscope, who discusses AI innovations in the drug development sector. AI can now analyze the immune system in HD, potentially revolutionizing clinical trials and drug development. Imagine predicting which candidates will respond best to treatment before it even begins 🔬 Tune in this week to hear about how AI continues to push the sector forward for quicker, better, and more innovative drug development. Find out more and be the first to listen: Spotify 👉 https://ow.ly/I5ET50PlzP0 Apple 👉 https://ow.ly/8kNF50PlzOZ Amazon 👉 https://ow.ly/M3WI50PlzP1] #AI #DrugDevelopment #ClinicalTrials

T cells' greatest strength lies in their specificity, but how is it achieved? Let’s find out more about our heroes, #TCells! 👇 #ScienceIsWeAll #NoTCellLeftBehind

Exciting T cell news! Antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful Tumor Infiltrating Lymphocyte (TIL) therapy were obtained from combinatorial peptide libraries and proteomic databases, and used to identify "orphan T Cells". The paper also studies multipronged T cells, made by combining multiple "orphan" TCRs, which have capacity to target multiple cancer-related antigens simultaneously and be a powerful tool in our fight against cancer. 🗞️ https://lnkd.in/djjx9_m4 #NoTCellLeftBehind #ScienceIsWeAll